

Investor News 02/25

October 29, 2025

NNIT RESTATES ITS LIFE SCIENCE SEGMENT IN ITS FINANCIAL REPORTING STRUCTURE

Today, NNIT announces an update to its financial reporting structure to ensure that all Life Sciences customers are fully consolidated under Region Europe, US, and Asia. As a result, all Life Science customers previously reported under Region Denmark irrespective of the business activity will now be included in Region Europe's profit and loss statement. Going forward, Region Denmark will consist solely of the Public segment and the Private segment, which includes SCALES.

The restatement of the Life Sciences segment has been implemented and will take effect with the release of the interim report for the first nine months of 2025, scheduled for November 4, 2025. In the interim report for the first nine months of 2025, NNIT will include the P&L for Region Europe and Region Denmark before and after the restatement. This will also be done for the reporting of Q4 2025.

Historical financial figures have been restated accordingly, effective from the first quarter of 2024 (see enclosed factsheet). This change only impacts the financials for Region Europe and Region Denmark; the profit and loss statements for the Group, Region US, and Region Asia remain unchanged.

Restated P&L for Region Europe & Region DK

Region Europe, DKKm	Q1 24		Q2 24		Q3 24		Q4 24		Q1 25		Q2 25	
	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated
Revenue	175.8	126.4	185.3	135.0	167.5	126.7	170.9	124.2	168.5	119.3	160.5	116.4
Production cost	132.8	97.2	141.5	101.2	137.2	101.5	131.1	91.6	128.2	92.3	126.4	90.8
Gross profit	43.0	29.2	43.8	33.8	30.2	25.2	39.8	32.6	40.3	27.0	34.1	25.6
Gross margin	24.5%	23.1%	23.6%	25.1%	18.0%	19.9%	23.3%	26.2%	23.9%	22.7%	21.3%	22.0%
Regional overhead cost	15.4	15.0	14.4	13.8	12.8	12.3	14.4	13.2	17.0	15.1	8.1	6.0
Regional operating profit	27.6	14.2	29.4	20.0	17.4	13.0	25.4	19.4	23.2	11.9	26.0	19.6
Regional operating profit margin	15.7%	11.2%	15.9%	14.8%	10.4%	10.3%	14.9%	15.6%	13.8%	10.0%	16.2%	16.8%
Corporate cost	16.1	12.5	14.0	11.2	18.4	14.3	12.4	9.3	21.1	15.4	18.9	13.8
Group operating profit before special items	11.4	1.6	15.4	8.8	-1.0	-1.3	13.0	10.1	2.1	-3.5	7.1	5.6
Group operating profit margin before special items	6.5%	1.3%	8.3%	6.5%	-0.6%	-1.0%	7.6%	8.1%	1.3%	-2.9%	4.4%	4.8%

Region DK, DKKm	Q1 24		Q2 24		Q3 24		Q4 24		Q1 25		Q2 25	
	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated	Restated	Bef. restated
Revenue	162.9	212.3	163.3	213.6	155.9	196.7	174.6	221.4	171.6	220.8	174.6	218.7
Production cost	119.1	154.7	124.1	164.4	112.0	147.8	144.3	183.8	135.8	171.7	136.3	171.9
Gross profit	43.8	57.6	39.2	49.1	43.9	48.9	30.4	37.6	35.8	49.1	38.2	46.8
Gross margin	26.9%	27.1%	24.0%	23.0%	28.2%	24.8%	17.4%	17.0%	20.9%	22.2%	21.9%	21.4%
Regional overhead cost	9.1	9.6	11.5	12.1	10.2	10.8	8.1	9.3	13.9	15.8	11.3	13.4
Regional operating profit	34.6	48.0	27.7	37.1	33.7	38.1	22.3	28.3	22.0	33.3	26.9	33.4
Regional operating profit margin	21.3%	22.6%	17.0%	17.4%	21.6%	19.4%	12.7%	12.8%	12.8%	15.1%	15.4%	15.3%
Corporate cost	22.3	25.9	16.2	19.1	19.8	23.9	12.2	15.3	20.3	26.0	19.2	24.3
Group operating profit before special items	12.3	22.1	11.5	18.0	13.9	14.2	10.0	13.0	1.7	7.3	7.7	9.2
Group operating profit margin before special items	7.6%	10.4%	7.0%	8.4%	8.9%	7.2%	5.7%	5.9%	1.0%	3.3%	4.4%	4.2%

Restated of Revenue growth & Organic growth for Region Europe & Region DK

Region Europe, DKKm	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	6M 24	9M 24	FY 24	6M 25
Before restatement										
Revenue growth, %	12.9%	13.3%	1.1%	14.4%	-5.6%	-13.8%	12.9%	8.9%	10.1%	-9.8%
Organic growth, %	12.2%	12.3%	0.6%	13.9%	-5.9%	-13.7%	12.3%	8.2%	9.5%	-9.9%
After restatement										
Revenue growth, %	13.0%	11.8%	2.3%	10.6%	-4.2%	-13.4%	12.4%	9.0%	9.4%	-8.9%
Organic growth, %	12.6%	11.0%	1.9%	10.3%	-4.3%	-13.3%	11.8%	8.4%	8.9%	-8.9%

Region Denmark, DKKr	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	6M 24	9M 24	FY 24	6M 25
Before restatement										
Revenue growth, %	29.4%	28.8%	0.3%	7.4%	4.0%	2.4%	29.2%	18.4%	15.3%	3.2%
Organic growth, %	18.0%	27.3%	0.3%	7.4%	4.0%	2.4%	22.7%	14.3%	12.3%	3.2%
After restatement										
Revenue growth, %	35.2%	37.0%	-1.1%	8.9%	5.4%	6.9%	36.1%	21.3%	17.7%	6.1%
Organic growth, %	19.7%	34.9%	-1.1%	8.9%	5.4%	6.9%	27.2%	16.0%	13.9%	6.1%

For more information, please contact:

Investor Relations

Carsten Ringius
EVP & CFO
Tel: +45 3077 8888
carr@nnit.com

Media Relations

Thomas Stensbøl
Press & Communications Manager
Tel: +45 3077 8800
tmts@nnit.com

ABOUT NNIT

NNIT is a leading provider of IT solutions to life sciences internationally, and to the public and private sectors in Denmark.

We focus on high complexity industries and thrive in environments where regulatory demands and complexity are high.

We advise on and build sustainable digital solutions that work for the patients, citizens, employees, end users or customers.

We strive to build unmatched excellence in the industries we serve, and we use our domain expertise to represent a business first approach – strongly supported by a selection of partner technologies but always driven by business needs rather than technology.

NNIT consists of group company NNIT A/S and the subsidiary SCALES. Together, these companies employ around 1,600 people in Europe, Asia and the USA.